Javascript must be enabled to continue!
Effect of Thymoquinone on Interleukin-8, FEV1, and COPD Assessment Test Score in Stable Chronic Obstructive Lung Disease
View through CrossRef
ABSTRACT Background: Chronic obstructive pulmonary disease (COPD), a persistent airway obstruction, is caused by continuous exposure to harmful particles or irritants. Airway inflammation contributes the pathogenesis of COPD. Thymoquinone, has an anti-inflammatory effect. This study aimed to examine the effect of thymoquinone on interleukin-8 (IL-8) level, percentage of FEV1, and COPD assessment test score (CAT) in stable chronic obstructive lung disease. Subjects and Method: A quasi-experiment with pretest and posttest control group was conducted at the outpatient pulmonology unit, Dr. Moewardi, Surakarta, Central Java, from June to August 2019. A sample of 40 patients diagnosed with stable COPD was selected and allocated into two groups: (1) 20 patients treated with a combination of standard therapy and thymoquinone oil capsules 500 mg/ day; and (2) 20 patients treated with standard therapy. The dependent variables were IL-8 level, FEV1, and COPD assessment test score (CAT). The independent variables were treatment status. The data were analyzed by the paired-t-test. Results: The level of IL-8 was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 14.35; SD= 3.95) than before treatment (Mean= 19.62; SD= 12.14), and it was not statistically significant (p= 0.052). The percentage of FEV1 was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 42.36; SD= 14.43) than before treatment (Mean= 42.56; SD= 16.09), and it was not statistically significant (p= 0.943). The CAT score was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 13.70; SD= 4.24) than before treatment (Mean= 13.70; SD= 4.24) than before treatment (Mean= 18.65; SD= 5.92), and it was statistically significant. Conclusion: Chronic obstructive pulmonary disease assessment test (CAT) score significantly decreases with the treatment combination of standard COPD therapy and thymoquinone oil capsules 500 mg/ day. Keywords: Thymoquinone, stable COPD, IL-8, FEV1, CAT score Correspondence: Yusup Subagio Sutanto. Department of Pulmonology and Respiratory Medicine, Dr. Moewardi Hospital Surakarta. Jl. Kolonel Soetarto No. 132 Surakarta, Central Java. Email: dr_yusupsubagio@yahoo.com. Mobile: +62811284165. DOI: https://doi.org/10.26911/the7thicph.05.34
Masters Program in Public Health, Universitas Sebelas Maret
Title: Effect of Thymoquinone on Interleukin-8, FEV1, and COPD Assessment Test Score in Stable Chronic Obstructive Lung Disease
Description:
ABSTRACT Background: Chronic obstructive pulmonary disease (COPD), a persistent airway obstruction, is caused by continuous exposure to harmful particles or irritants.
Airway inflammation contributes the pathogenesis of COPD.
Thymoquinone, has an anti-inflammatory effect.
This study aimed to examine the effect of thymoquinone on interleukin-8 (IL-8) level, percentage of FEV1, and COPD assessment test score (CAT) in stable chronic obstructive lung disease.
Subjects and Method: A quasi-experiment with pretest and posttest control group was conducted at the outpatient pulmonology unit, Dr.
Moewardi, Surakarta, Central Java, from June to August 2019.
A sample of 40 patients diagnosed with stable COPD was selected and allocated into two groups: (1) 20 patients treated with a combination of standard therapy and thymoquinone oil capsules 500 mg/ day; and (2) 20 patients treated with standard therapy.
The dependent variables were IL-8 level, FEV1, and COPD assessment test score (CAT).
The independent variables were treatment status.
The data were analyzed by the paired-t-test.
Results: The level of IL-8 was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 14.
35; SD= 3.
95) than before treatment (Mean= 19.
62; SD= 12.
14), and it was not statistically significant (p= 0.
052).
The percentage of FEV1 was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 42.
36; SD= 14.
43) than before treatment (Mean= 42.
56; SD= 16.
09), and it was not statistically significant (p= 0.
943).
The CAT score was lower after treatment with combination of standard therapy and thymoquinone oil capsules 500 mg/ day (Mean= 13.
70; SD= 4.
24) than before treatment (Mean= 13.
70; SD= 4.
24) than before treatment (Mean= 18.
65; SD= 5.
92), and it was statistically significant.
Conclusion: Chronic obstructive pulmonary disease assessment test (CAT) score significantly decreases with the treatment combination of standard COPD therapy and thymoquinone oil capsules 500 mg/ day.
Keywords: Thymoquinone, stable COPD, IL-8, FEV1, CAT score Correspondence: Yusup Subagio Sutanto.
Department of Pulmonology and Respiratory Medicine, Dr.
Moewardi Hospital Surakarta.
Jl.
Kolonel Soetarto No.
132 Surakarta, Central Java.
Email: dr_yusupsubagio@yahoo.
com.
Mobile: +62811284165.
DOI: https://doi.
org/10.
26911/the7thicph.
05.
34.
Related Results
Innate immunity and its link to clinical outcomes in smokers with and without COPD
Innate immunity and its link to clinical outcomes in smokers with and without COPD
<p dir="ltr">Chronic obstructive pulmonary disease (COPD) is the fourth most common causes of death globally, affecting around ten percent of the adult population. Patients w...
Innate immunity and its link to clinical outcomes in smokers with and without COPD
Innate immunity and its link to clinical outcomes in smokers with and without COPD
<p dir="ltr">Chronic obstructive pulmonary disease (COPD) is the fourth most common causes of death globally, affecting around ten percent of the adult population. Patients w...
Time to Start Up: CT-Basted Radiomics in Children’s Lung Diseases
Time to Start Up: CT-Basted Radiomics in Children’s Lung Diseases
Radiomics is a new interdisciplinary field and a fusion product consisting by large data technology and medical image to aid diagnosis. Radiomics can gather information from differ...
Relationship between the COPD assessment test (CAT) and respiratory function characteristics of North African stable COPD patients
Relationship between the COPD assessment test (CAT) and respiratory function characteristics of North African stable COPD patients
Introduction: The COPD Assessment Test (CAT) is a simple method for assessing the impact of COPD on the patient`s health which is not validated with North African COPD patients.
O...
Impaired lung function and the development of cardiovascular disease
Impaired lung function and the development of cardiovascular disease
<p dir="ltr">Impaired lung function is a prevalent condition in the general population, posing a significant risk for morbidity and mortality. There is a well-documented asso...
Impaired lung function and the development of cardiovascular disease
Impaired lung function and the development of cardiovascular disease
<p dir="ltr">Impaired lung function is a prevalent condition in the general population, posing a significant risk for morbidity and mortality. There is a well-documented asso...
Efficacy of Ensifentrine in Chronic Obstructive Pulmonary Disease (COPD): A Meta-analysis of Randomized Controlled Trials
Efficacy of Ensifentrine in Chronic Obstructive Pulmonary Disease (COPD): A Meta-analysis of Randomized Controlled Trials
Abstract
Background: Chronic obstructive pulmonary disease (COPD) presents significant management challenges, as many patients continue to experience daily sympto...
Phenotypic Differences between Patients with Smoking Chronic Obstructive Pulmonary Disease and Non-smoking Chronic Obstructive Pulmonary Disease
Phenotypic Differences between Patients with Smoking Chronic Obstructive Pulmonary Disease and Non-smoking Chronic Obstructive Pulmonary Disease
Background:
In low- and middle-income countries, causes other than tobacco smoking contribute more to the development of chronic obstructive pulmonary disease (COPD). I...

